CIHR Implements Mandatory Clinical Trial Registration and Results Disclosure Policy

In a significant move toward greater transparency in clinical research, the Canadian Institutes of Health Research (CIHR) has announced mandatory requirements for clinical trial registration and results disclosure. The policy affects all researchers who received CIHR funding for clinical trials from 2022 onwards, making compliance essential for maintaining future funding eligibility.

Compliance Monitoring and Enforcement

Starting February 2025, CIHR will implement a systematic monitoring process to ensure researchers adhere to the new transparency requirements. The organization plans to publish compliance reports in spring 2025, introducing a new level of accountability in Canadian clinical research.

Impact on Research Community

The mandate represents a crucial step in advancing research transparency and reducing publication bias in clinical trials. Researchers must now ensure their trials are properly registered and results are disclosed, regardless of whether the outcomes are positive or negative. This requirement aligns with global efforts to improve the accessibility and reliability of clinical trial data.

Registration Requirements

Under the new policy, investigators must register their clinical trials and provide comprehensive results disclosure. This systematic approach ensures that valuable research data, whether favorable or unfavorable, becomes part of the public scientific record. The policy aims to prevent selective reporting and enhance the overall quality of clinical research in Canada.

Funding Implications

For researchers, compliance with these requirements is not optional. CIHR has explicitly tied future funding eligibility to adherence to these transparency measures. This approach underscores the organization's commitment to open science and evidence-based medicine, while also providing a strong incentive for researchers to maintain transparent reporting practices.